CCA
APLS

Catalyst Capital Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Catalyst Capital Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-172
Closed -$4K – 303
2019
Q3 		$4K Buy
+172
New +$4.73K ﹤0.01% 410
2018
Q1 		– Sell
-345
Closed -$7K – 479
2017
Q4 		$7K Buy
+345
New +$5.08K ﹤0.01% 355

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Catalyst Capital Advisors's APLS Position: Q4 2019 in Review

Catalyst Capital Advisors sold out of Apellis Pharmaceuticals (APLS) in Q4 2019, closing a stake of 172 shares — an estimated $4K sold.

Catalyst Capital Advisors first reported a position in APLS in Q4 2017 and held it in 2 quarters. The position peaked at $7K in Q4 2017. 133 funds tracked by Wall St. Rank hold APLS as of Q4 2019.

  • Catalyst Capital Advisors reported no remaining Apellis Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 172 Apellis Pharmaceuticals shares in Q4 2019, an estimated $4K.
  • Catalyst Capital Advisors first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Catalyst Capital Advisors's Apellis Pharmaceuticals position peaked at $7K in Q4 2017.
  • 133 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2019.

Based on Catalyst Capital Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.